Breakthrough prospiciens studium: PCR-fundatur sanguis Ctdna methylation technology opens novum era MRD custodire Colorectal Cancer

Nuper, Jama (si 33.012) published an magna Result Results [I] per Cancer Cancer de CAI CAI CANNA CARCIRGIENCHI CANNA COLLECTUM Stratification ad Colecular RELICTUM Morbus et Periculum Via Circulating in III Colorectal Tumor DNA Methylation et Periculum Stratification). " Hoc studium est prima multicenter studium in hoc mundo adhibere PCR-fundatur sanguis ctdna multigene methylation technology pro coloreectal cancer recursu, et recursu et recursu, quod expectatur magis sumptus, quodcumque CORPONGING et SOLUTIO CIRCUMSPECTO PATERTIDATIONE Technology et MRD CALORETAL CIRCUMSPECTATIONEM PATERTIDENTIA PATERTITUDO et CORPORTALIS CORPORATUS PATERTITATIONE et VRECTURITIAE et VENDITIO PERPENTICIBUS et Qualis est Vestibulum . Et studium erat etiam altus aestimari per Journal et ejus editors, et quod enumerantur ut a key commendaticiis charta in hac proventus, et Professor Juan Ruiz-Bañobre ex Hispania et Professor Ajay Goel ex Civitatibus Foederatis Americae et invitari ad review. De studio et nuntiavit per Genomeweb, a ducens biomedical media in Civitatibus Foederatis Americae.

Colorectal cancer (CRC) est commune malignus tumore gastrointestinal tractus in Sina. MMXX Internationalis Agency ad Research in Cancer (IARC) notitia ostendere quod 555,000 novum casibus in Sinis propter circiter 1/3 de mundo, cum incidentiae rate saltu ad secundum locum communi carcinomata in Sinis; 286,000 Mortibus ob circiter 1/3 mundi, ordo ut quintus maxime commune causa cancer mortes in Sinis. Quintus causa mortis in Sinis. Est notabile quod inter diagnosed aegros, in TNM stages I, II, III et IV sunt 18,6%, 42.5%, 30.7% et 8.2% respectively. Plus quam LXXX% de aegris sunt in medio et sera et in ac XLIV% eorum simultaneous vel heterochronic distant metastases ad iecoris et pulmonis, qui graviter afficiunt et causa gravibus sociali et oeconomica onus. Secundum ad Statistics National Cancer Center, in Mediocris annua incremento in sumptus colorectal cancer curatio in Sina est de 6.9% ad 9,2% et personalis salutem potest accipere LX% in unum annum reditus. Cancri aegros sunt patiens a morbo et etiam sub magna oeconomica pressura [II].
Nonaginta sentio de coloreectal cancer laesiones potest removeri surgically, et ante Tumor est deprehenditur, in altiorem quinque annos superessendam rate post radicalis post radicalis resection est adhuc circiter XXX%. Quinque-annus superessendam rates of colorectal cancer in Seres population sunt 90.1%, 72.6%, 53.8% et 10,4% ad gradus I, II, III et IV, respective.
Minimal RELICTUM Morbus (MRD) est a major causa tumore recursu post radicalis curatio. In annis, mrd deprehendatur technology pro solidum tumores habet provectus cursim, et plures heavyweight observational et interventus studiis confirmavit quod postoperative MRD status potest indicare periculo postoperative Retrenage of Colorectal Cancer. CTDNA Testing habet commoda entis noninvasive, simplex, celeri, cum princeps specimen accessibility et vincere tumor heterogeneum.
US NCCN guidelines pro colonia cancer et Chinese csco guidelines pro coloreectal cancer et statu quod pro postoperative recursu periculum determinationem et adjuvant chemotherapy lectio in colonia et predictive notitia ut adiuvaret in adjuvant curatio et predictive in aegris cum scaena II vel Colon Cancer. Sed maxime existentium studia focus in CTDNA mutationum secundum summus throughput sequencing technology (ngs), quae habet complex processus, diu plumbum tempus, et excelsum et humilis invaluisset in aegris.
In casu de scaena III Colorectal cancer aegros, NGS, secundum CTDNA Dynamic Cras costs usque ad $ 10,000 ad unum visit et postulat a exspectantes tempus ad duo weeks. Cum multigene methylation test in hoc studio, colonaiq®, aegros potest habere dynamic ctdna magna ad decimam de sumptus et a fama in ut paulo ut duo dies.
According to the 560,000 new cases of colorectal cancer in China each year, the clinical patients mainly with stage II-III colorectal cancer (the proportion is about 70%) have more urgent demand for dynamic monitoring, then the market size of MRD dynamic monitoring of colorectal cancer reaches millions of people each year.
Potest videri, quod investigationis results habere magna scientific et practica significationem. Per magnam, scale futurum orci studiis, confirmavit quod PCR-fundatur sanguinem Ctdna multigene methylation technology potest adhiberi colorectal cancer recursivity, exaltatione et recursu, efficaciam, melior enabling exaltatione et costae, melioris aegris. In studium fundatur in colonaiq®, a multi-gene methylation test for colorectal cancer developed per Kuny, cuius orci applicationem valorem in mane protegendo et diagnosi confirmata a centralis orci studio.
Gastroenterology (IF33.88), in Top International Acta in agro Gastrointestinal morbis in MMXXI, nuntiavit in multicency investigationis eventus Zhongshan hospitalis de Fudan University, Cancer in Colonai Coloni Coloni et Early Early Early diagnose Colorectal cancer, et initio exploratur etiam explores potential applicationem in prognosis vigilantia de coloreectal cancer.

Ad Praeterea validate in orci applicationem CTDNA Methylation in Periculum Stratification, Guiding Treatment Decisions et mane Recursence Cras in scaena I-III Colorectal Cancer Surgery et Collection Sangueci Cancer CCXCIX, qui sequantur, et in Steam Suspendisse Septimi, qui in unum septimana, et in unum mensem post surgery, una mensis post surgery, et postoperative postulatos post surgery, et postoperative postputant cum surgery, et in una mensis postputant cum surgery, et in unum mensem postputant cum surgery, et in una mensis postputant postoperative post surgery, et in una mensis postputant postoperative post surgery, et in una mense post surgery, una mensis post surgery, et in postoperative postoperative post surgery, et postoperative postputant post surge Therapy ad dynamicam sanguinem CTDNA temptationis.
Primo, quod inventa est quod CTDNA temptationis posset praedicere periculum recursu in coloreectal cancer aegris mane, tam preoperatively et mane postoperatively. Preopative CTDNA, positivum aegros habebat altiorem probabilitatem postoperative recursu quam preoperative ctdna, negans aegris (22.0%> 4.7%). Mane postoperative ctdna temptationis tamen praedicta recursu Risk: una mensis post radicalis resection, ctdna, positivum aegros 17,5 temporibus magis verisimile recurrit quam negans aegris; In quadrigis et invenit quod combined CTDNA et CEA testing paulo melius perficientur in detecting recursu (AUC = 0.849), sed differentia non significant comparari ctdna (AUC = 0.839).
CHINICUS CHORAGIUM combined cum Periculum factores est currently in pelagus basis periculum stratification de cancer aegros, et in current paradigma, magna numerus aegris et sub-treatment in inhaero. Secundum hoc, in quadrigis classificatis aegros cum gradu III Colorectal cancer in diversis subgroups secundum orci recursu Risk Taxationem (High Periculum (T1-3N1)) et Adjuvant Treatment (3/6 mensibus. In analysis invenit quod aegris in summus periculo subgroup CTDNA positivum aegros habuit inferiorem recursu rate si receperunt sex menses adjuvant justo; In humili-periculo subgroup ctdna, positivum aegros, non fuit significant differentia inter adjuvant curatio cycle et patientes estote eventus; Dum CTDNA, negans aegris habebat significantly melius deploratae quam CTDNA, positivum aegros et iam postoperative recursu-liberum periodum (RFS); scaena et humilis-periculo gradu II coloreectal cancer omnes ctdna, negans aegris non recursu in duobus annis; Ideo integratio CTDNA cum orci features expectat ut porro optimize periculum stratification et melior praedictum recursu.

Figura I. Playsma CTDNIS Analysis in Pom1 ad mane Deprehensionem Colorectal Cancer Recursence
Further results of dynamic ctDNA testing showed that the risk of recurrence was significantly higher in patients with positive dynamic ctDNA testing than in patients with negative ctDNA during the disease recurrence monitoring phase after definitive treatment (after radical surgery + adjuvant therapy) (Figure 3ACD), and that ctDNA can indicate tumor recurrence up to 20 months earlier than imaging (Figure 3B), offering the possibility of Mane deprehendatur morbo recursu et opportune interventu.

Figura II. CTDNIS Analysis secundum Longitudinal Cohort ad deprehendere coloreectal cancer recursu

"A numerus of translational medicina studiis in Colorectal Cancer ducere disciplinam, praesertim CTDNA-fundatur MRD Testis demonstrat magna potential ad augendae postoperative procuratio periculo strativing, gubernat curatio decisiones et mane recursu magna.

Utilitas eligens DNA methylation ut nove MRD titulum super mutationem deprehensio est quod non requirit totam genome sequencing protegendo tumore textuum, quod directe propter deprehendatur somaticosque falsum ex normalis propter deprehendatur, et vitat falsum ex normalis propter deprehendatur, et vitat falsum ex normalis exeuntibus, benignum et vitat, et clonal hematopoiesis.
Hoc studiis et aliis related studiis confirmare quod CTDNA, secundum MRD Testing est maxime momenti sui iuris periculum factor pro recursu de scaena I-III Colorectal Cancer et potest esse ad Auxilium Rectum Treatment I-III CORPORTAL CANCER.
Et in agro MRD est celeriter evolving cum multis innovative, altus sensitiva et specifica assays secundum epigeneticis (DNA methylation et fragmenter,) et genomics sequencing, aut tota-altum). Nos expecto quod colonaiq® continues ut organize magna-scale orci studiis et fieri novum indicator de mrd testing quod combines accessibility, princeps perficientur et affordability et potest late in exercitatione orci usu. "
References
[I] Mo s, L, Wang D, Han L, Zhou s, Wang H, Dai Wang Y, Luo S, Wang R, Xu Morbi et Periculum Via Circulating Tumor DNA Metal. Jama Oncol. MMXXIII Apr XX.
[II] "Onus Colorectal Cancer morbo in Seres population: habet mutata in annis? , Seres Acta Epidemiology, Vol. XLI, No. X, October MMXX.
[III] Tarazona n, Gimeno, valiente F, Gambardella V, et al. Targeted Next-generation Sequencing de Circulating-Tumor DNA ad tracking minima RELICTU morbo in localized colonia cancer. Ann Oncol. Nov I, MMXIX; XXX (XI) 1804-1812.
[IV] Taieb J, André T, Aulin E. conflans adjuvant Therapy ad non-metastatic colonia cancer, novum signa et prospectus. Cancri Tractare D.nus MMXIX; LXXV: 1-11.